Research programme: CD3-CD123 bispecific antibodies- Sanofi

Drug Profile

Research programme: CD3-CD123 bispecific antibodies- Sanofi

Alternative Names: CD123 CODV TCE

Latest Information Update: 27 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sanofi
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia

Most Recent Events

  • 21 Apr 2018 Pharmacodynamics and pharmacokinetics data from a preclinical study in Acute myeloid leukaemia presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
  • 09 Apr 2018 Preclinical trials in Acute myeloid leukaemia in France (unspecified route)
  • 29 Nov 2017 Sanofi files for patent protection with EPO for anti-cd3 antibodies, anti-cd123 antibodies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top